+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Low prevalence of HCV, HIV, and HTLV-I/II infection markers in northwestern Greece: results of a 3-year prospective donor study (1995-1997)



Low prevalence of HCV, HIV, and HTLV-I/II infection markers in northwestern Greece: results of a 3-year prospective donor study (1995-1997)



European Journal of Internal Medicine 14(1): 39-44



Background: The risk of infection with transfusion-transmitted viruses has been reduced remarkably. A zero-risk blood supply, however, remains a popular goal. A 3-year prospective donor study was conducted in the Epirus region of Greece to determine the prevalence of human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B virus, and hepatitis C virus (HCV). Herein, we report the prevalence of HIV, HTLV, and HCV infection markers in this area. Methodology: Between January 1, 1995 and December 31, 1997, 6696 donors were investigated for the presence of anti-HIV, anti-HTLV, and anti-HCV antibodies using standard enzyme immunoassays (EIA). Every sample with anti-HCV reactivity by third-generation EIA was further investigated using a third-generation recombinant immunoblot assay (RIBA 3.0) and HCV-RNA by a combination of polymerase chain reaction (PCR) and DNA EIA. Results: None of the donors tested positive for anti-HIV or anti-HTLV antibodies. In contrast, anti-HCV was detected in 41 donors (0.61%). Using a RIBA 3.0 test, eight donors tested positive and eight had indeterminate results, while 25 tested negative. Seven of the eight donors with both EIA and RIBA 3.0 reactivity had increased levels of aminotransferases and detectable serum HCV-RNA. The remaining 34 donors had repeatedly normal aminotransferases and three times negative HCV-RNA. Liver biopsy was performed in anti-HCV/HCV-RNA-positive donors (7/41). The lesions were compatible with chronic hepatitis C in all of them. Conclusion: A zero prevalence of HIV and HTLV infection markers was found. Although the number of annual donations in this study was relatively low, the negative data for HIV and HTLV clearly indicate that rates of these infections are low in our region and that infected donors will be seen infrequently. HCV infection in blood donors remains very low in our region and is similar to the data reported in other industrialized countries. In fact, the prevalence of definite HCV infection seems to be very low (7/6696; 0.1%). However, a significant proportion of anti-HCV-reactive donors by third-generation EIA (33/41) had indeterminate or negative results by the RIBA 3.0. The latter donors were repeatedly negative for HCV-RNA. This finding may indicate that some donors tested false-positive for anti-HCV, although the possibility of true HCV infection contracted in the distant past cannot be excluded. In our opinion, close attention to mandatory principles of transfusion medicine, along with the screening of plasma donors using nucleic acid amplification technology, are the only methods that can further ensure the safety of our blood supply.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046579518

Download citation: RISBibTeXText

PMID: 12554009

DOI: 10.1016/s0953-6205(02)00185-1


Related references

Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 41(5): 652-658, 2001

Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. Journal of Hepatology 59(5): 949-956, 2013

Results from the moth monitoring scheme in northwestern Russia 1995-97 Luoteis-Venajan yoperhosseurannan tulokset 1995-1997. Baptria (Helsinki): 234: 219-230, 1998

Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. Journal of Clinical Microbiology 33(7): 1735-1738, 1995

Three-year prospective study of HTLV-III/LAV infection in homosexual men. Lancet 1(8491): 1179-1182, 1986

A 3-year prospective study of infection with HIV (=LAV/HTLV III) in homosexuals. Zeitschrift für Hautkrankheiten 61(16): 1133-1134, 1986

Prevalence of HTLV-I and HTLV-II infection in Gabon, Africa: comparison of the serological and PCR results. International Journal of Cancer 49(3): 373-376, 1991

The natural history of HTLV-I infection Results from a prospective epidemiologic study. AIDS Research & Human Retroviruses 10(Suppl. 1): S111, 1994

Prevalence and incidence of viral markers in Croatian blood donors 1995-1997. Vox Sanguinis 74(Suppl. 1): 1141, 1998

Prevalence of chronic HBV infection among 13,581 women at reproductive age in Greece. A prospective single center study. Journal of Clinical Virology 32(2): 179-180, 2005

A three year prospective study of infection with the htlv iii virus in initially symptom free homosexual men in london. Qjm5: 1074, 1986

Laboratory test differences associated with HTLV-I and HTLV-II infection. Retrovirus Epidemiology Donor Study Investigators. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17(4): 332-338, 1998

HTLV-I infection in Barbados Results of a 20-year follow-up study. AIDS Research & Human Retroviruses 10(4): 475, 1994

Prevalence of infection by HTLV-I/II among pregnant women and high-risk groups in the Peloponnese peninsula, Greece. International Journal of Std and Aids 17(8): 543-546, 2006

Annual to interannual variations of fCO2 in the northwestern Mediterranean Sea: results from hourly measurements made by CARIOCA buoys, 1995-1997. Journal of: 3-31, 2001